Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

@article{Schultz1994NeoadjuvantCF,
  title={Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.},
  author={Ph. Schultz and Harry W. Herr and Zhifang Zhang and Dean F Bajorin and Andrew Seidman and Antoine Sarkis and William R. Fair and Diane Scherr and George J. Bosl and Howard I. Scher},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 7},
  pages={
          1394-401
        }
}
PURPOSE To determine survival in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and to analyze prechemotherapy and postchemotherapy factors for prognostic significance. PATIENTS AND METHODS The survival of 111 patients with T2-4N0M0 bladder cancer treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) was assessed. Prechemotherapy and postchemotherapy factors were analyzed for correlation with survival. Factors found to be… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Similar Papers

Loading similar papers…